Portal or subcutaneous insulin infusion: Efficacy and impact on liver inflammation

Fundamental and Clinical Pharmacology

Volumn 29, Issue 5, 2015, Pages 488-498

  Dal, Stéphanie ^a   Jeandidier, Nathalie ^b   Schaschkow, Anaïs ^a   Spizzo, Anne Hélène ^b   Seyfritz, Elodie ^a   Sookhareea, Cynthia ^a   Bietiger, William ^a   Péronet, Claude ^a   Moreau, François ^b   Pinget, Michel ^b   Maillard, Elisa ^a   Sigrist, Séverine ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Diabetes; Glycogen; Insulin therapy; Liver function

Indexed keywords

ALPHA 2 MACROGLOBULIN; FRUCTOSAMINE; GLUCOSE; GROWTH HORMONE RECEPTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STREPTOZOCIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN-LIKE GROWTH FACTOR-1, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CELL INFILTRATION; COMPARATIVE EFFECTIVENESS; CONTINUAL INTRAPERITONEAL INSUPLANT INFUSION; CONTINUAL SUBCUTANEOUS INSUPLANT INFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL HEPATITIS; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; INFUSION SYSTEM; INSULIN INFUSION; INSULIN PUMP; LIPID PEROXIDATION; LIVER FUNCTION; LIVER METABOLISM; MACROPHAGE; MALE; METABOLIC REGULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HEPATITIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER FUNCTION TEST; METABOLISM; PATHOLOGY; PORTAL VEIN; SUBCUTANEOUS DRUG ADMINISTRATION; WISTAR RAT;

ALPHA-MACROGLOBULINS; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FRUCTOSAMINE; HEPATITIS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN-LIKE GROWTH FACTOR I; LIPID PEROXIDATION; LIVER; LIVER FUNCTION TESTS; MACROPHAGES; MALE; OXIDATIVE STRESS; PORTAL VEIN; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84941742886     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12129     Document Type: Article

References (50)

1. Selam J.L., Kashyap M., Alberti K.G. et al. Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. Metabolism (1989) 38 908-912.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329 977-986.
3. Schade D.S., Eaton R.P., Friedman N.M., Spencer W.J. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia (1980) 19 35-39.
4. Selam J.L., Bergman R.N., Raccah D., Jean-Didier N., Lozano J., Charles M.A. Determination of portal insulin absorption from peritoneum via novel nonisotopic method. Diabetes (1990) 39 1361-1365.
5. Selam J.L., Raccah D., Jean-Didier N., Lozano J.L., Waxman K., Charles M.A. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care (1992) 15 53-58.
6. Broussolle C., Jeandidier N., Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet (1994) 343 514-515.
7. Jeandidier N., Selam J.L., Renard E. et al. Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group. Diabetes Care (1996) 19 780.
8. Pinget M., Jeandidier N. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps. Horm. Metab. Res. (1998) 30 475-486.
9. Schaepelynck P., Renard E., Jeandidier N. et al. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. Diabetes Technol. Ther. (2011) 13 657-660.
10. Monti L.D., Piatti P.M., Home P.D., Tomson C., Alberti K.G. The effect of intraperitoneal insulin delivery on carbohydrate metabolism in type 1 (insulin-dependent) diabetic patients. Diabetes Res. Clin. Pract. (1992) 15 237-244.
11. Baron A.D., Wallace P., Olefsky J.M. In vivo regulation of non-insulin-mediated and insulin-mediated glucose uptake by epinephrine. J. Clin. Endocrinol. Metab. (1987) 64 889-895.
12. Micossi P., Bosi E., Cristallo M. et al. Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII). Acta Diabetol. Lat. (1986) 23 155-164.
13. Ruotolo G., Micossi P., Galimberti G. et al. Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metabolism (1990) 39 598-604.
14. Bagdade J.D., Kelley D.E., Henry R.R., Eckel R.H., Ritter M.C. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes (1997) 46 414-420.
15. Hanaire-Broutin H., Sallerin-Caute B., Poncet M.F. et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia (1996) 39 1498-1504.
16. Monnier L., Colette C., Owens D. Basal insulin analogs: from pathophysiology to therapy. What we see, know, and try to comprehend? Diabetes Metab. (2013) 39 468-476
17. Russell-Jones D.L., Rattray M., Wilson V.J., Jones R.H., Sonksen P.H., Thomas C.R. Intraperitoneal insulin is more potent than subcutaneous insulin at restoring hepatic insulin-like growth factor-I mRNA levels in the diabetic rat: a functional role for the portal vascular link. J. Mol. Endocrinol. (1992) 9 257-263.
18. Arias P., Kerner W., de la Fuente A., Pfeiffer E.F. Abnormal growth hormone levels in insulin-dependent diabetic patients under continuous subcutaneous insulin infusion and intensified conventional treatment. Acta Endocrinol. (1984) 107 250-255.
19. Kobayashi K., Amemiya S., Sawanobori E. et al. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care (1997) 20 1442-1447.
20. Rudolf M.C., Coustan D.R., Sherwin R.S. et al. Efficacy of the insulin pump in the home treatment of pregnant diabetics. Diabetes (1981) 30 891-895.
21. Scott C.D., Baxter R.C. Production of insulin-like growth factor I and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetic rats. Endocrinology (1986) 119 2346-2352.
22. Hedman C.A., Frystyk J., Lindstrom T., Oskarsson P., Arnqvist H.J. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion. Clin. Endocrinol. (2014) 81 58-62
23. Shishko P.I., Dreval A.V., Abugova I.A., Zajarny I.U., Goncharov V.C. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res. Clin. Pract. (1994) 25 1-12.
24. Wanless I.R., Bargman J.M., Oreopoulos D.G., Vas S.I. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod. Pathol. (1989) 2 69-74.
25. Meyer L., Jeantroux J., Riveline J.P. et al. Reversible focal hepatic steatosis in type 1 diabetic patients treated with intraperitoneal insulin implantable pump therapy. Diabetes Care (2008) 31 e49.
26. Nakazawa I., Ohtsuki M., Goto Y. The lipid-chemical features of the metastatic tissues into the liver from the human gastric cancer, large intestinal cancer and malignant insulinoma. Tohoku J. Exp. Med. (1978) 126 95-101.
27. Jackson S., Mager D.R., Bhargava R. et al. Long-term follow-up of hepatic ultrasound findings in subjects with magnetic resonance imaging defined hepatic steatosis following clinical islet transplantation: a case-control study. Islets (2013) 5 16-21.
28. Leitao C., Peixoto E., Westphalen A. et al. Liver fat accumulation after islet transplantation and graft survival. Cell Transplant. (2014) 23 1221-1227.
29. Santini S.A., Marra G., Giardina B. et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes (1997) 46 1853-1858.
30. Al-Domi H., Alzweiri M., Hamdan I., Jaradat Z. In vitro evaluation of potential complexation between bovine insulin and bovine serum albumin. Biomed. Chromatogr. (2014) 28 428-432
31. Gustavsson C., Yassin K., Wahlstrom E. et al. Sex-different hepatic glycogen content and glucose output in rats. BMC Biochem. (2010) 11 38.
32. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. (1976) 72 248-254.
33. Dal-Ros S., Oswald-Mammosser M., Pestrikova T. et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology (2010) 138 1574-1584.
34. Rhoads R.P., Kim J.W., Leury B.J. et al. Insulin increases the abundance of the growth hormone receptor in liver and adipose tissue of periparturient dairy cows. J. Nutr. (2004) 134 1020-1027.
35. Butler S.T., Marr A.L., Pelton S.H., Radcliff R.P., Lucy M.C., Butler W.R. Insulin restores GH responsiveness during lactation-induced negative energy balance in dairy cattle: effects on expression of IGF-I and GH receptor 1A. J. Endocrinol. (2003) 176 205-217.
36. White M.F. The IRS-signalling system in insulin and cytokine action. Philos. Trans. R. Soc. Lond. B Biol. Sci. (1996) 351 181-189.
37. Cong L.N., Chen H., Li Y. et al. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol. Endocrinol. (1997) 11 1881-1890.
38. Jinbo T., Motoki M., Yamamoto S. Variation of serum alpha2-macroglobulin concentration in healthy rats and rats inoculated with Staphylococcus aureus or subjected to surgery. Comp. Med. (2001) 51 332-335.
39. Jinbo T., Sakamoto T., Yamamoto S. Serum alpha2-macroglobulin and cytokine measurements in an acute inflammation model in rats. Lab. Anim. (2002) 36 153-157.
40. van Westrhenen R., Westra W.M., van den Born J. et al. Alpha-2-macroglobulin and albumin are useful serum proteins to detect subclinical peritonitis in the rat. Perit. Dial. Int. (2006) 26 101-107.
41. Nathan D.M., Dunn F.L., Bruch J. et al. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am. J. Med. (1996) 100 412-417.
42. Farese R.V. Insulin-sensitive phospholipid signaling systems and glucose transport. Update II. Exp. Biol. Med. (Maywood) (2001) 226 283-295.
43. Farese R.V., Sajan M.P., Standaert M.L. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp. Biol. Med. (Maywood) (2005) 230 593-605.
44. Niswender K.D., Gallis B., Blevins J.E., Corson M.A., Schwartz M.W., Baskin D.G. Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. J. Histochem. Cytochem. (2003) 51 275-283.
45. Tanti J.F., Grillo S., Gremeaux T., Coffer P.J., Van Obberghen E., Le Marchand-Brustel Y. Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. Endocrinology (1997) 138 2005-2010.
46. Kakkar R., Mantha S.V., Radhi J., Prasad K., Kalra J. Increased oxidative stress in rat liver and pancreas during progression of streptozotocin-induced diabetes. Clin. Sci. (1998) 94 623-632.
47. Inoue M., Jiang Y., Barnes R.H. 2nd et al. Thrombospondin 1 mediates HFD-induced muscle fibrosis and insulin resistance in male mice. Endocrinology (2013) 154 4548-4559
48. Levine S.A., Kidd P.M. Antioxydant adaptation. Its aole in free radical pathology. Allergy Research Group, San Leandro, USA, 1994, pp. 48-51.
49. Vos F.E., Manning P.J., Sutherland W.H., Schollum J.B., Walker R.J. Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: a randomized controlled pilot study. Nephrology (2011) 16 68-75.
50. Wang Z., Liu L., Hu T. et al. Protective effect of glucose-insulin-potassium (GIK) on intestinal tissues after severe burn in experimental rats. Burns (2012) 38 846-854.